|
|
|
市場調查報告書
傳染病疫苗開發平台:競爭檢討
Special Report: The Infectious Disease Vaccine Pipeline--A Competitive Review
|
傳染病疫苗開發平台:競爭檢討 是由出版商Decision Resources, Inc.在2011年06月所出版的。
這份英文市場調查報告書價格從美金9200起跳。
傳染病疫苗開發的平台穩，由於疫苗的開發而有許多疫苗可用。但是HIV等病徵目前對第一線疫苗的需求仍然很高，還有流感及白喉、百日咳等一般性疫苗在安全性及有效性上皆還有改善的空間。這些未滿足需求更進一步推動了疫苗的開發。
本報告提供以美國為中心的全球傳染病疫苗市場趨勢，彙整新興疫苗概要，2006∼2017年的市場預測等資料，為您概述為以下內容。
摘要整理
簡介
傳染病疫苗開發平台
- 傳染病疫苗的背景
- 藥物
- 企業
- GlaxoSmithKline
- Sanofi
- Merck & Co
- 其他的企業
傳染病疫苗的未滿足需求和機會
- 有效HIV疫苗
- 並用的兒童用疫苗
- 替代的施打方法
- 通用的流感疫苗
市場統計與今後的預測
圖表
Abstract
Introduction:
The infectious disease (ID) vaccine pipeline is robust (vetted to 164 agents
from an initial list of 585 total vaccines in clinical development across all
therapeutic areas), a notable finding given the long length of time it takes
to develop a vaccine and the many vaccines already available. However,
indications such as HIV have high demand for the development of a first
vaccine, and even routine vaccinations, such as those for influenza or
diphtheria, tetanus, and pertussis (DTP), can be improved in terms of safety
and efficacy. Such unmet needs are driving the continued development of ID
vaccines.
Questions Answered in This Report:
- Vaccinations are in development for a wide array of infectious diseases,
from those for which vaccines already exist to those for which no vaccines are
on the market. Why is this variety of vaccines needed? Which diseases are
receiving the most attention from developers?
- Physicians (ID specialists, PCPs, and pediatricians) surveyed by Decision
Resources have diverse opinions regarding the unmet needs of the ID vaccine
pipeline. What are the diseases with the greatest unmet need in terms of
vaccines, according to each physician specialty? Is there any consensus among
the specialties regarding unmet needs?
- The ID vaccine market is poised to grow 15% over 2010-2017. What is the
projected size of the market during this period? How is year-over-year market
growth expected to increase or decline over this time frame?
Scope:
- Markets covered: United States, rest of world (ROW).
- Primary research: February/March 2011 survey of 106 ID specialists,
PCPs, and pediatricians.
- Emerging vaccines: Phase I: 73 vaccines; Phase II: 64 vaccines;
Phase III: 20 vaccines; filed: 7 vaccines.
- Market forecast features: Market statistics of the ID vaccine
market from 2006 through 2017.
- Data-rich content: 42 tables and figures that detail our pipeline,
market, and survey data.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- The Infectious Disease Vaccine Pipeline
- Infectious Disease Vaccine Background
- Agents
- Companies
- GlaxoSmithKline
- Sanofi
- Merck & Co
- Other Companies
- Select ID Vaccine Unmet Needs and Opportunities
- An Effective HIV Vaccine
- Combination Pediatric Vaccines
- Alternative Delivery Methods
- A Universal Flu Vaccine
- Market Statistics and Market Outlook
- Market Statistics
- Market Outlook
- Flu Vaccines
- Emerging Markets
- HIV Vaccines
Tables
- 1. Infectious Diseases for Which Vaccines Are Currently Used
- 2. Categories of Infectious Disease Vaccines
- 3. Leading Infectious Disease Vaccine Pipelines: Number of Vaccines
by Company and Phase
- 4. Leading Infectious Disease Vaccine Pipelines: Number of Vaccines
by Company and Indication
- 5. GlaxoSmithKline' s Infectious Disease Vaccine Pipeline
- 6. Sanofi' s Infectious Disease Vaccine Pipeline
- 7. Merck & Co.' s Infectious Disease Vaccine Pipeline
- 8. Worldwide Sales of Leading Infectious Disease Vaccines, 2010
- 9. Market-Leading Companies by Sales of Infectious Disease
Vaccines, 2010
- 10. Market-Leading Companies by Sales of Infectious Disease
Vaccines, 2017
- 11. Worldwide Sales of Leading Infectious Disease Vaccines, 2017
Figures
- 1. Survey Question: Please rank the following infectious diseases
in order of unmet needs with regard to vaccines
- 2. Vaccine Pipeline, by Infectious Disease
- 3. Survey Question: Considering not just the size of the at-risk
population, please select from the following list the top three pathogen types
for which emerging prophylactic vaccines would deliver the greatest overall
benefit
- 4. Survey Question (ID Specialists): If a prophylactic vaccine for
any of the following infectious diseases is approved, do you believe it will
be recommended for a routine immunization schedule?
- 5. Survey Question (PCPs): If a prophylactic vaccine for any of the
following infectious diseases is approved, do you believe it will be
recommended for a routine immunization schedule?
- 6. Survey Question (Pediatricians): If a prophylactic vaccine for
any of the following infectious diseases is approved, do you believe it will
be recommended for a routine immunization schedule?
- 7. Survey Question: If a prophylactic vaccine for any of the
following infectious diseases is approved, what percentage of the population
do you think will receive it?
- 8. Infectious Disease Vaccine Pipeline, by Phase of Development
- 9. Infectious Disease Vaccine Pipeline: Prophylactic vs.
Therapeutic Vaccines
- 10. Infectious Disease Vaccine Pipeline, by Delivery Method
- 11. Infectious Disease Vaccine Pipeline, by Technology
- 12. Infectious Disease Vaccine Pipeline, by Company/Agency
- 13. Infectious Disease Vaccine Pipeline: Development Activity by
Company Size
- 14. GlaxoSmithKline Infectious Disease Vaccine Franchise Sales,
2010 and 2017
- 15. Survey Question: Are you aware of GlaxoSmithKline' s emerging
combination vaccine Menhibrix?
- 16. Survey Question: Are you aware of GlaxoSmithKline' s emerging
malaria vaccine, Mosquirix?
- 17. Survey Question: Are you aware of GlaxoSmithKline' s emerging
combination vaccine Nimenrix?
- 18. Survey Question: Are you aware of GlaxoSmithKline' s emerging
varicella zoster virus vaccine (herpes zoster)?
- 19. Sanofi' s Infectious Disease Vaccine Franchise Sales, 2010 and
2017
- 20. Survey Question: Are you aware of Sanofi' s emerging influenza
vaccine, Fluzone ID?
- 21. Survey Question: Are you aware of Sanofi' s emerging dengue
fever vaccine?
- 22. Merck & Co.' s Infectious Disease Vaccine Franchise Sales, 2010
and 2017
- 23. Survey Question: Are you aware of Merck' s emerging HPV vaccine,
V-503?
- 24. Survey Question: Are you aware of Novartis' s emerging influenza
vaccine, OptaFlu?
- 25. Survey Question: Are you aware of Merck' s emerging
meningococcal B vaccine, MenB?
- 26. Survey Question: Are you aware of Dynavax Technologies'
emerging hepatitis B vaccine, Heplisav?
- 27. Survey Question: What is your opinion regarding administration
of three to four pediatric vaccines simultaneously?
- 28. Survey Question: Of the following unmet needs regarding
vaccines in clinical practice, please select the top three that you feel are
the greatest
- 29. Worldwide Infectious Disease Vaccine Market Growth, 2006-2017
- 30. Worldwide Infectious Disease Vaccine Market Growth, by Region,
2006-2017
- 31. Worldwide Sales of Infectious Disease Vaccines, by Type, 2010
and 2017
|
 |
